← TRDA
TRDA— Entrada Therapeutics, Inc.
MaterialsPharmaceutical Preparations
| Metric | FY2021 | FY2020 |
|---|---|---|
| Research and development | $35.9M+70.2% | $21.1M |
| General and administrative | $15.2M+173.2% | $5.6M |
| Total operating expenses | $51.1M+91.7% | $26.7M |
| Loss from operations | -$51.1M-91.7% | -$26.7M |
| Interest and other (expense) income, net | -$31K-121.5% | $144K |
| Total other (expense) income, net | -$31K-121.5% | $144K |
| Net loss | -$51.2M-92.9% | -$26.5M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$8K+66.0% | -$24K |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$8K+66.0% | -$24K |
| Weighted-average common shares outstanding, basic (in shares) | $6.27B+467.1% | $1.11B |
| Weighted-average common shares outstanding, diluted (in shares) | $6.27B+467.1% | $1.11B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.